1,2 The results are consistent with actions taken by the European Medicines Agency (EMA) in June 2025, when the agency classified NAION as a very rare side effect of semaglutide and recommended product labeling updates. Epidemiologic data reviewed by the EMA suggested an approximately twofold increased risk in adults with type 2 diabetes, corresponding to roughly one additional case per 10,000 person-years of treatment. The agency advised that patients with sudden vision loss or rapidly worsening eyesight seek immediate medical attention and discontinue treatment if NAION is confirmed. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation Study strengths Methodologically, the VA study offers several strengths: The analysis leveraged the largest integrated health care system in the United States, with medication exposure confirmed through pharmacy dispensing records rather than prescription data alone
84 Vitamin E plus pioglitazone (Actos) (an anti-diabetes drug) in particular has been shown in multiple clinical trials to effectively treat NASH and reduce fibrosis
Transform your body care routine with YARIN DeeJang Body Soap Scrub, enriched with tomato extract, glutathione, and collagenyour skins new secret to achieving a smooth, glowing look
Swissmedic is currently evaluating Eli Lillys pill orfoglipron
Thats important, but a more important message is to treat our diabetic patients with this group of agents
In rare cases, more serious issues like pancreatitis or gallbladder complications have been reported
